OTHER INFORMATION.
−Removed: Rule 10b5-1 Trading Plans
−Removed: On August 31, 2023 , Christine Chung , Senior Vice President , China Operations of the Company, terminated a Rule 10b5-1 trading plan, which was previously adopted on March 7, 2023 and intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
−Removed: The plan provided for the potential sale of up to 125,000 shares of common stock held by Ms.
−Removed: Prior to its termination, Ms.
−Removed: Chung sold 12,500 shares under the plan.
−Removed: On July 12, 2023 , Mark Eisner , then Chief Medical Officer of the Company, terminated a Rule 10b5-1 trading plan, which was previously adopted on March 2, 2023 and intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
−Removed: The plan provided for the potential sale of up to 107,260 shares of common stock held by Mr.
−Removed: Prior to its termination, Mr.
−Removed: Eisner sold 0 shares under the plan.
−Removed: On August 31, 2023 , Juan Graham , Chief Financial Officer of the Company, terminated a Rule 10b5-1 trading plan, which was previously adopted on August 26, 2022 and intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
−Removed: The plan provided for the potential sale of up to 29,911 shares of common stock held by Mr.
−Removed: Prior to its termination, Mr.
−Removed: Graham sold 7,929 shares under the plan.
−Removed: On September 22, 2023 , Jeffrey Henderson , a member of the Company’s Board of Directors , terminated a Rule 10b5-1 trading plan, which was previously adopted on March 3, 2023 and intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
−Removed: The plan provided for the potential sale of up to 20,000 shares of common stock held by Mr.
−Removed: Prior to its termination, Mr.
−Removed: Henderson sold 6,000 shares under the plan.
+Added: Rule 10b5-1 Trading Arrangements
Incorporation By Reference
5 unchanged sentences
and AstraZeneca AB, dated as of October 20, 2014.
−Removed: Offer Letter, dated July 23, 2023, between FibroGen, Inc.
−Removed: and Thane Wettig.
−Removed: Consulting Agreement, dated July 23, 2023, between FibroGen, Inc.
−Removed: and Enrique Conterno.
+Added: Amendment No.
+Added: 1 to the Exclusive License and Option Agreement, between FibroGen, Inc.
+Added: and HiFiBiO Inc., dated February 14, 2024.
+Added: Termination and Transition Agreement to Development and Commercialization Agreement (for the U.S.
+Added: and Certain Other Territories), by and between AstraZeneca AB and FibroGen, Inc., dated February 23, 2024, effective as of February 25, 2024.
+Added: Non-Employee Director Compensation Policy, as amended, dated April 22, 2024.
+Added: Offer Letter by and between FibroGen, Inc.
+Added: and Deyaa Adib, M.D., dated February 6, 2024.
Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).
9 unchanged sentences
Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)
+Added: * Filed herewith.
Portions of this exhibit (indicated by asterisks) have been omitted as the Company has determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm if publicly disclosed or is the type of information the Company treats as confidential.
2 unchanged sentences
FibroGen, Inc.
−Removed: November 6, 2023
/s/ Thane Wettig
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 6, 2023
/s/ Juan Graham
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.